PCI Biotech appoints Dr Hans Olivecrona as Chief Medical Officer
Oslo (Norway), 23 August 2017 - PCI Biotech (OSE: PCIB), a cancer focused
biopharmaceutical company is pleased to announce the appointment of Dr. Hans
Olivecrona MD PhD as Chief Medical Officer (CMO). Dr Olivecrona will also serve
as a member of PCI Biotech's executive management team. He will lead the
execution of all clinical development programmes, and be a key contributor to
the identification and implementation of new opportunities and pipeline
expansions.
Dr Olivecrona brings extensive experience in the development and
commercialisation of novel therapeutics. In his most recent role, Dr. Olivecrona
held the position as Senior Medical Director at Swedish Orphan Biovitrum (Sobi
AB) in Stockholm, Sweden, with the responsibility for medical affairs and all
medical aspects of business development for Sobi's international partner product
portfolio. Prior to this, Dr Olivecrona held various positions spanning from
preclinical and clinical development to regulatory interactions. Dr Olivecrona
has a PhD from the Karolinska Institute and his work experience includes 20
years of academic clinical background, mainly within oncological surgery with a
specialty in gastrointestinal cancers. Dr Olivecrona also headed a hospital
research facility and is the author of numerous scientific publications.
Per Walday, CEO, comments: "We are delighted to welcome Dr Olivecrona to PCI
Biotech. With his broad scientific, clinical and business development background
he will bring important knowhow and experience to our organisation, as we move
towards a potential pivotal development phase for our lead programme fimaChem. "
Dr Hans Olivecrona added: "I am very excited to be joining PCI Biotech at what
is clearly an important stage for the company. The encouraging fimaChem Phase I
data in inoperable perihilar bile duct cancer may pave the way for expedited
development and market entrance to the benefit of this underserved patient
population. I am also very much looking forward to working on the development of
the exciting fimaVacc and fimaNac assets."
Contact information:
Per Walday, CEO
pw@pcibiotech.no
Mobile: +47 917 93 429
About PCI Biotech
PCI Biotech is a biopharmaceutical company focusing on development and
commercialisation of novel therapies for the treatment of cancer through its
innovative photochemical internalisation (PCI) technology platform. PCI is
applied to three distinct anticancer paradigms: fimaChem (enhancement of
chemotherapeutics for localised treatment of cancer), fimaVacc (T-cell induction
technology for therapeutic vaccination), and fimaNAc (nucleic acid therapeutics
delivery).
Photochemical internalisation induces triggered endosomal release that is used
to unlock the true potential of a wide array of therapeutic modalities. The
company's lead fimaChem programme consists of a clinical Phase I/II clinical
study in bile duct cancer, an orphan indication with a high unmet need and
without approved products. fimaVacc applies a unique mode of action to enhance
the essential cytotoxic effect of therapeutic cancer vaccines, which works in
synergy with several other state-of-the-art vaccination technologies. fimaNAc
utilises the endosomal release to provide intracellular delivery of nucleic
acids, such as mRNA and RNAi therapeutics, thereby addressing one of the major
bottlenecks facing this emerging and promising field.
For further information, please visit: www.pcibiotech.com
Forward-looking statements
This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.
PCI Biotech disclaims any obligation to update or revise any forward-looking
statements, whether as a result of new information, future events or otherwise.
This information is subject to the disclosure requirements pursuant to section
5 -12 of the Norwegian Securities Trading Act.